The importance of reducing cardiovascular risk in patients with type 2 diabetes
This eLearning module has been commissioned and funded by the Boehringer Ingelheim and Lilly Alliance and developed in partnership with Guidelines in Practice and Guidelines Learning. Products are discussed. This eLearning module is intended for healthcare professionals.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain or Northern Ireland
PC-GB-105237 September 2021